https://doi.org/10.1016/S1473-3099(24)00507-3

IF 36.4 1区医学 Q1 INFECTIOUS DISEASES

Lancet Infectious Diseases Pub Date : 2024-11-04 DOI:10.1016/s1473-3099(24)00732-1

{"title":"https://doi.org/10.1016/S1473-3099(24)00507-3","authors":"","doi":"10.1016/s1473-3099(24)00732-1","DOIUrl":null,"url":null,"abstract":"Babiker A, Warner S, Li X, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3—In this Article, the members of the NIH-Antimicrobial Resistance Outcomes Research Initiative have been updated. This correction has been made to the online version as of Nov 4, 2024 and will be made to the printed version.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"241 1","pages":""},"PeriodicalIF":36.4000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3\",\"authors\":\"\",\"doi\":\"10.1016/s1473-3099(24)00732-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Babiker A, Warner S, Li X, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3—In this Article, the members of the NIH-Antimicrobial Resistance Outcomes Research Initiative have been updated. This correction has been made to the online version as of Nov 4, 2024 and will be made to the printed version.\",\"PeriodicalId\":49923,\"journal\":{\"name\":\"Lancet Infectious Diseases\",\"volume\":\"241 1\",\"pages\":\"\"},\"PeriodicalIF\":36.4000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s1473-3099(24)00732-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s1473-3099(24)00732-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

Babiker A, Warner S, Li X, et al.2016年至2021年美国195家医院对β-内酰胺类药物治疗的侵袭性A组链球菌感染患者进行毒素抑制的辅助利奈唑胺与克林霉素：一项目标试验仿真的回顾性队列研究。Lancet Infect Dis 2024；10月10日在线发表。https://doi.org/10.1016/S1473-3099(24)00507-3-在本文中，NIH-抗菌药耐药性结果研究计划的成员已被更新。截至 2024 年 11 月 4 日，在线版本已作此更正，印刷版本也将进行更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Correction to Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3

Babiker A, Warner S, Li X, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis 2024; published online Oct 10. https://doi.org/10.1016/S1473-3099(24)00507-3—In this Article, the members of the NIH-Antimicrobial Resistance Outcomes Research Initiative have been updated. This correction has been made to the online version as of Nov 4, 2024 and will be made to the printed version.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Infectious Diseases 医学-传染病学

CiteScore

60.90

自引率

0.70%

发文量

1064

审稿时长

6-12 weeks

期刊介绍： The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.